Personalized Medical Care & Dedicated International Patient Concierge

4.9 Patient Satisfaction

en-US

Medical Clinic LogoMedical ClinicHome
Book Consultation
Book Consultation
Patient Guide
SpecialtiesServicesDoctorsOffersArticlesBefore & AfterReviewsAbout UsContact Us
US Regenerative Medicine Regulations vs. South Korea's Advanced Regenerative Framework

Medical Guide

US Regenerative Medicine Regulations vs. South Korea's Advanced Regenerative Framework

A neutral guide to US FDA rules for cells and tissues, the RMAT designation, and South Korea's regenerative framework. Approval is not proof.

Schedule a Consultation

Medically reviewed by Dr. Seok Lee, Lead Physician, Pentaheal Medical Group

Patients researching stem-cell and regenerative treatments quickly discover that the rules governing them differ from country to country, and that the differences can be confusing. A treatment that is offered legally in one place may be considered investigational or unapproved somewhere else. This does not mean one country is "right" and another is "wrong"; it means that different regulatory systems draw their lines in different places, for different historical and policy reasons.

The purpose of this article is to explain, neutrally and accurately, how the United States regulates human cells and tissues, what the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation actually is, and how South Korea's dedicated advanced-regenerative-medicine framework fits into the picture. It is educational, not promotional. Most importantly, it carries a single unifying message that applies to every framework discussed here: a legal permission is not the same as proof that a treatment works, and being permitted under one country's system is not US-FDA approval. If you would like to discuss how any of this applies to your own situation, you can reach the Pentaheal Medical Group team.

How the US Regulates Human Cells and Tissues

In the United States, the FDA regulates human cells, tissues, and cellular and tissue-based products — often abbreviated HCT/Ps — under 21 CFR Part 1271. This regulatory framework is the backbone of how stem-cell and regenerative products are overseen domestically, and it establishes a crucial distinction that shapes everything else: the difference commonly described as "361" versus "351."

Under this framework, some HCT/Ps are regulated solely under Section 361 of the Public Health Service Act. To fall into this lighter-touch category, a product generally must meet specific criteria — for example, being only minimally manipulated, being intended for a use that matches its original biological function (a concept known as homologous use), and meeting other defined conditions. Products that meet all of these criteria are subject mainly to requirements aimed at preventing the transmission of communicable disease, and they do not require premarket approval.

When a cell or tissue product does not meet those "361" criteria — for instance, because it is more than minimally manipulated or is intended for a non-homologous use — the FDA regulates it as a drug, device, or biological product. These are the "351" products, named for Section 351 of the Public Health Service Act. Critically, a "351" product must go through the FDA's premarket review process and be shown to be safe and effective before it can be lawfully marketed. As the FDA explains in its consumer materials on tissue and tissue products, this distinction is central to understanding why some products can be offered without premarket approval while many stem-cell and regenerative products cannot.

The practical takeaway is that many of the stem-cell and regenerative offerings marketed directly to patients would, under US rules, fall into the "351" category and therefore require approval that most have not obtained. That is a major reason the FDA has warned about unapproved products.

What the RMAT Designation Really Is

One of the most commonly misunderstood elements of US regulation is the Regenerative Medicine Advanced Therapy (RMAT) designation. Because the name contains the word "advanced," it is sometimes mistaken for a seal of approval or an endorsement of a specific clinic's treatment. It is neither.

RMAT is a designation created to expedite the development and review of regenerative medicine therapies that are intended to treat serious or life-threatening conditions and for which there is preliminary clinical evidence suggesting the therapy may address unmet medical needs. A therapy that receives RMAT designation may become eligible for more frequent interaction with the FDA and other features intended to speed development — but the therapy still must go through the full process and be proven safe and effective before it can be approved and lawfully marketed.

In other words, RMAT is a designation that helps promising candidate therapies move through development more efficiently. It is not itself an approval, and it is not something a clinic offering a service to patients can point to as evidence that its specific treatment is proven. Understanding RMAT correctly helps you see the difference between a therapy that is being rigorously developed within the US system and a product that is simply being marketed.

It is also worth noting why the US built a designation like RMAT in the first place. Regenerative medicine is a fast-moving field, and regulators have tried to create routes that encourage genuine scientific development without lowering the ultimate evidentiary bar. The existence of an expedited pathway signals that the FDA takes the promise of these therapies seriously — but it does so precisely because those therapies still have to earn approval through data. Reading RMAT as a shortcut around proof gets the intent exactly backward: the designation exists to make disciplined development faster, not to make marketing easier.

South Korea's Advanced Regenerative Medicine Framework

South Korea has a dedicated legal framework for advanced regenerative medicine. This framework permits certain regenerative treatments to be provided under its own defined system, with its own rules, oversight bodies, and requirements. It reflects a national policy decision to create a specific legal pathway for regenerative and cell-based care.

Pentaheal Medical Group operates within this Korean context. The clinic's regenerative services are provided under South Korea's advanced and regenerative-medicine framework and the Ministry of Health & Welfare's foreign-patient registration. These are legitimate Korean designations that describe the legal basis on which the clinic operates and its registration to care for international patients.

The reason different countries land in different places is partly historical and partly a matter of policy priorities. Regulatory systems balance the desire to make promising treatments available against the duty to protect patients from unproven or unsafe products, and different jurisdictions strike that balance differently. Neither approach is inherently superior; they simply reflect distinct legal traditions and decisions about how much evidence should be required before a treatment can be offered, and under what conditions.

Here is where neutrality and precision matter most. A permission granted under South Korea's framework is exactly that — a permission under South Korea's framework. It is not US-FDA approval. The two systems are separate, and a treatment being lawfully offered in South Korea does not mean the FDA has reviewed it, cleared it, or found it to be safe and effective. Neither does it mean the opposite; it simply means the two frameworks are distinct and should not be conflated. A patient comparing options needs to hold both facts at once: the Korean permission is real, and it is not equivalent to US approval.

The Point Both Systems Share

It is tempting to treat regulation as a proxy for effectiveness — to assume that if something is legally permitted, it must work, or that if it is not FDA-approved, it must be worthless. Both assumptions are too simple.

The more accurate statement is this: neither pathway, by itself, proves that a particular treatment works for an individual. US regulation sets requirements that "351" products must meet approval before marketing, and that is a high evidentiary bar — but the RMAT designation and the "361" category are not, in themselves, proof of effectiveness for any specific use. South Korea's framework permits certain treatments under its own system, but a legal permission is not a demonstration of proven efficacy either. Regulatory status tells you about the legal and oversight environment surrounding a treatment; it does not substitute for evidence about whether that treatment will help you.

This is also why the FDA has issued both a broad warning about stem-cell therapies and a specific consumer alert on regenerative medicine products, including stem cells and exosomes. Those communications caution that many products marketed to patients are unapproved and that some have been linked to serious harms. The regulatory framing is not meant to endorse or condemn any single clinic; it is meant to help patients understand that marketing and legality are not the same as proof, and that unapproved products can carry real risks.

What This Means for a Patient's Decision

If you are weighing a regenerative treatment offered under a framework outside the United States, a neutral and honest checklist helps:

  • Understand the regulatory status precisely. Ask which country's framework a treatment is provided under and what that framework does and does not certify. Do not assume that legal permission abroad equals US-FDA approval.
  • Recognize what a designation is. RMAT is a development-and-review designation, not an approval. A "361" classification is a regulatory category, not proof of effectiveness.
  • Separate regulation from evidence. Ask what clinical evidence, if any, supports the specific treatment for your specific situation — independently of its legal status.
  • Take FDA warnings seriously. The FDA's warning and consumer alert exist because unapproved regenerative products have been associated with real harms. That caution applies regardless of where a treatment is offered.
  • Ask about undisclosed details. If a clinic's public materials do not specify important details, such as the source of the cells used, raise those questions directly during consultation.

How Pentaheal Frames This

Pentaheal Medical Group is a functional, regenerative, and longevity-focused clinic in the Seocho District of Seoul. It describes a diagnostics-first model: a functional health evaluation, precision diagnostic testing, and personalized treatment planning, delivered through a 1:1 physician model with Dr. Seok Lee personally involved, with virtual consultations available before travel and a dedicated international patient team for overseas patients. The clinic states that Dr. Lee is the Lead Physician and a graduate of Chung-Ang University College of Medicine, with more than 20 years in functional, regenerative, stem-cell, and anti-aging medicine; these are the clinic's stated facts, not claims of superior outcomes.

Consistent with the regulatory reality described above, the clinic's own outcome language is exploratory — phrases such as "studied for their potential" and "may support" — rather than definitive. Programs are described as structured pathways of roughly 7 to 14 days, a deposit is required to confirm a booking with the balance due before the program begins, and specific costs and candidacy are confirmed at consultation. You can learn more about the clinic's model on the Pentaheal Medical Group website. None of this changes the central point of this article: the appropriate way to evaluate any regenerative treatment is on its evidence and your individual medical circumstances, discussed with a qualified physician — not on regulatory labels alone.

Bottom Line

The United States regulates human cells and tissues (HCT/Ps) under 21 CFR Part 1271, drawing a key line between "361" products that can be offered without premarket approval and "351" products that must be proven safe and effective before marketing. The RMAT designation is a tool to expedite the development of promising therapies that still must be proven and approved — it is not an approval itself. South Korea maintains a dedicated advanced-regenerative-medicine framework that permits certain treatments under its own system. A Korean legal permission is not US-FDA approval, and neither pathway, by itself, proves that a treatment works. Evaluate regenerative options on evidence and your own medical situation, and take FDA warnings seriously. To discuss your questions, you can contact Pentaheal Medical Group.

Frequently Asked Questions

**Does a treatment being legal in South Korea mean it is FDA-approved?**No. A treatment permitted under South Korea's advanced-regenerative-medicine framework is authorized under that Korean system only. It is not US-FDA approval. The two regulatory systems are separate, and a legal permission in one country does not mean the FDA has reviewed or approved the treatment.

**What is the difference between "361" and "351" products?**Under 21 CFR Part 1271, "361" products meet specific criteria (such as being only minimally manipulated and intended for homologous use) and can be offered without premarket approval, subject mainly to disease-transmission safeguards. "351" products do not meet those criteria and are regulated as drugs, devices, or biologics that must be proven safe and effective before marketing.

**Is RMAT designation the same as FDA approval?**No. The Regenerative Medicine Advanced Therapy designation is intended to expedite the development and review of promising therapies for serious conditions. A therapy with RMAT designation still must complete the process and be proven safe and effective before it can be approved. RMAT is not an approval and not an endorsement of any clinic's service.

**Does regulatory approval prove a treatment will work for me?**Regulatory status describes the legal and oversight environment around a treatment; it is not the same as proof that a treatment will help you as an individual. Neither the US framework's categories nor Korea's permissions, by themselves, guarantee effectiveness. Ask about the specific clinical evidence and discuss your own circumstances with a physician.

**Why has the FDA warned about regenerative products?**The FDA has issued a broad warning about stem-cell therapies and a consumer alert on regenerative medicine products, including stem cells and exosomes, because many are unapproved and some have been associated with serious harms such as infections. The warnings are meant to help patients understand that marketing and legality do not equal proven safety or effectiveness.

This article is for general educational purposes only and is not medical advice; please consult a qualified physician about your individual situation.

More Articles

Continue reading our clinical guides.

View All
Korean Board-Certified Care: Safety in Functional Medicine Standards

Korean Board-Certified Care: Safety in Functional Medicine Standards

Chronic spine, joint, and cancer-related pain affects millions of families across South Korea.

Learn More

Learn More
Functional Medicine Clinic Seoul Korea | PENTAHEAL Guide

Functional Medicine Clinic Seoul Korea | PENTAHEAL Guide

Discover Seoul Korea's top functional medicine clinic for Americans. PENTAHEAL's complete guide to autoimmune, chronic disease and longevity programs in 2026.

Learn More

Learn More
Metabolic Syndrome Treatment Seoul Korea: The PENTAHEAL Protocol

Metabolic Syndrome Treatment Seoul Korea: The PENTAHEAL Protocol

Seeking metabolic syndrome treatment Seoul Korea? PENTAHEAL Medical Group offers a 1:1 metabolic reset program led by Dr. Seok Lee. Book your consult today.

Learn More

Learn More

Medical Clinic

Dedicated to evidence-based medical care, personalized treatment planning, and comprehensive support for local and international patients.

Treatments

SpecialtiesServicesMedical TeamSpecial OffersMedical Articles

Patient Guide

About UsHow It WorksBefore & AfterPatient ReviewsPress & Media

Information & Legal

Contact & LocationSite SearchPrivacy PolicyRefund & Cancellation PolicyTerms of Use

© Medical Clinic. All rights reserved.

Individual clinical results may vary. Please consult a board-certified specialist.